Cocrystal Pharma opened lower at $0.99, compared with its previous close of $1.02. In the last trading session, the stock traded between $0.99 and $1.04. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Cocrystal Pharma is now worth
$ 8.92
Resulting in a loss of
$ 91.08 (91.08%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.02 (-2.35%)
Day High
$1.04
Day Low
$0.99
Day Open
$0.99
Prev Close
$1.02
Volume
21,061
1W Return
-1.68%
1M Return
-5.59%
3M Return
-8.62%
6M Return
-23.38%
1Y Return
-11.86%
Fundamentals
Market Cap ($ Mn)
19
PE Ratio
-
PB Ratio
14.53
PEG Ratio
-
ROE
-122.11%
ROCE
-104.59%
EPS (TTM)
$-0.23
Investment Returns
1 Week
-1.68%
1 Month
-5.59%
3 Months
-8.62%
6 Months
-23.38%
9 Months
4.34%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.2
Mar 26
0.1
Jun 26
Updates
17Aug
Cocrystal Pharma appoints Carol Brosgart to its Board of Directors
Cocrystal Pharma (NASDAQ: COCP) has appointed Carol Brosgart, MD, to its Board of Directors effective August 12, 2026. Dr. Brosgart brings decades of experience in antiviral drug development, having contributed to FDA-approved therapies at Gilead Sciences. Her appointment aims to enhance the company's scientific oversight as it advances CDI-988 for norovirus and other pipeline assets.
2mo ago
13Aug
Cocrystal Pharma Q2 Results: EPS Loss Widens to $(0.23), Misses Estimate
Cocrystal Pharma's Q2 results show an EPS loss of $(0.23), missing estimates by 43.75% and widening 15% YoY from $(0.20). Sales remained at $105.000 thousand. The divergence between flat revenue and expanding losses indicates margin pressure.
3mo ago
3Aug
Cocrystal Pharma secures $5 million from OPKO Health for norovirus program
Cocrystal Pharma, Inc. completed a $5 million private placement with OPKO Health, Inc., issuing 5,474,053 shares at $0.9134 each. The funds support the Phase 1b clinical trial for norovirus candidate CDI-988, with topline data expected in late 2026. The deal includes no warrants or derivatives, providing clean equity capital ahead of a critical clinical milestone.
